Showing results (61-70 of 98) with videos related to
Sort By:
Pageof 10
Lancet (London, England)|February 17, 2009
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trialAnnie M Young, Lucinda J Billingham, Gulnaz Begum, et al.Anticancer Research|March 10, 2015
Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trialMegan J McGregor, Wakkas Fadhil, Rose Wharton, et al.Hepatology (Baltimore, Md.)|November 5, 2008
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaDaniel H Palmer, Rachel S Midgley, Noweeda Mirza, et al.Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.The New England Journal of Medicine|July 27, 2007
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerDavid J Kerr, Janet A Dunn, Michael J Langman, et al.Molecular Cancer Research : MCR|January 3, 2025
Coevolution of Atypical BRAF and KRAS Mutations in Colorectal TumorigenesisConnor E Woolley, Enric Domingo, Juan Fernandez-Tajes, et al.International Journal of Cancer|April 25, 2022
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndromeKatie Watts, Christopher Wills, Ayman Madi, et al.The Journal of Pathology|November 21, 2012
Use of multivariate analysis to suggest a new molecular classification of colorectal cancerEnric Domingo, Rajarajan Ramamoorthy, Dahmane Oukrif, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trialRachel S Midgley, Christopher C McConkey, Elaine C Johnstone, et al.The Lancet. Oncology|September 24, 2016
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialRachel S Kerr, Sharon Love, Eva Segelov, et al.Pageof 10